OnyeeChanMD

PubMed

• CML and the WHO: Why?
  Ellin Berman, Neil P Shah, Michael Deninger, Jessica K Altman, Maria Amaya, Kebede Begna, Ravi Bhatia, Onyee Chan, Robert Collins, Peter Curtin, Daniel J DeAngelo, Mic...> ;Journal of Clinical Oncology. 2024 Mar 20
• Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.
  Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda Deutsch, Ling Zhang, Mohammad Hussaini, Jinming Song, Seon...> ;Blood Advances. 2024 Mar 12
• Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
  Neil P Shah, Ravi Bhatia, Jessica K Altman, Maria Amaya, Kebede H Begna, Ellin Berman, Onyee Chan, Joan Clements, Robert H Collins, Peter T Curtin, Daniel J DeAngelo, ...> ;Journal of the National Comprehensive Cancer Network. 2024 Feb 1
• 1 citations
  TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
  Ayalew Tefferi, Farah Fleti, Onyee Chan, Najla H Al Ali, Aref Al-Kali, Kebede H Begna, James M Foran, Talha Badar, Nandita Khera, Mithun Shah, Devendra Hiwase, Eric Pa...> ;British Journal of Haematology. 2024 Apr 1
• Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.
  Nathan P Horvat, Enas F Abdallah, Zhuoer Xie, Najla Al Ali, Seongseok Yun, Alison Walker, Eric Padron, David Sallman, Onyee Chan, Jeffrey Lancet, Rami Komrokji, Andrew...> ;Annals of Hematology. 2024 Jan 1
• Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia.
  Somedeb Ball, Akriti G Jain, Chen Wang, Mohammad O Hussaini, Onyee Chan, Seongseok Yun, Andrew Kuykendall, Eric Padron, Kendra Sweet, Jeffrey E Lancet, Rami S Komrokji...> ;American Journal of Hematology. 2023 Dec 1
• 18 citations
  Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.
  Najla Al Ali, David A Sallman, Somedeb Ball, Akriti G Jain, Onyee Chan, Sara M Tinsley-Vance, Andrew Kuykendall, Kendra Sweet, Jeffrey E Lancet, Eric Padron, Rami S Ko...> ;Leukemia. 2023 Jul 1
• 2 citations
  Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes.
  Rami S Komrokji, Luis E Aguirre, Najla H Al Ali, Onyee Chan, Zhuoer Xie, Andrew Kuykendall, Kendra Sweet, Jeffrey E Lancet, Eric Padron, David A Sallman> ;Blood Advances. 2023 Jul 25
• 2 citations
  TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases.
  Farah Fleti, Onyee Chan, Amritpal Singh, Maymona G Abdelmagid, Aref Al-Kali, Michelle A Elliott, Kebede H Begna, James M Foran, Talha Badar, Nandita Khera, Najla H Al ...> ;American Journal of Hematology. 2023 Apr 1
• 2 citations
  Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.
  Yumeng Zhang, Lynn Nguyen, Chuanyi M Lu, Endi Wang, Marietya I S Lauw, Somedeb Ball, Ning Dong, Lynn Moscinski, Onyee Chan, Seongseok Yun, David Sallman, Lubomir Sokol...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Mar 1
• 1 citations
  Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients.
  Somedeb Ball, Akriti G Jain, Najla Al Ali, Sara M Tinsley, Onyee Chan, Andrew T Kuykendall, Kendra Sweet, Jeffrey E Lancet, David A Sallman, Mohammad Omar Hussaini, Er...> ;Leukemia Research. 2023 Jan 1
• 10 citations
  Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome.
  Rami S Komrokji, Avani M Singh, Najla Al Ali, Onyee Chan, Eric Padron, Kendra Sweet, Andrew Kuykendall, Jeffrey E Lancet, David A Sallman> ;Blood Cancer Journal. 2022 Nov 4
• 1 citations
  MPN-521 Somatic Mutational Landscape and Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors Among Patients With Myeloid and Lymphoid Neoplasms With Eosin...
  Yumeng Zhang, Chuanyi Lu, Endi Wang, Lynh Nguyen, Marietya Lauw, Somedeb Ball, Ning Dong, Lynn Moscinski, Onyee Chan, Seongseok Yun, David Sallman, Lubomir Sokol, Bija...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
• 6 citations
  Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations.
  Somedeb Ball, Todd C Knepper, Yehuda E Deutsch, Wassim Samra, Justin M Watts, Terrence J Bradley, Onyee Chan, Mohammad Omar Hussaini, Ling Zhang, Kendra L Sweet, Andre...> ;Cancer. 2022 Nov 1
• 2 citations
  Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates.
  Andrew T Kuykendall, Qianxing Mo, David A Sallman, Najla Al Ali, Onyee Chan, Seongseok Yun, Kendra L Sweet, Eric Padron, Jeffrey E Lancet, Rami S Komrokji> ;Cancer. 2022 Oct 1
• 3 citations
  Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
  Virginia O Volpe, Najla Al Ali, Onyee Chan, Eric Padron, David A Sallman, Andrew Kuykendall, Kendra Sweet, Jeffrey E Lancet, Rami S Komrokji> ;British Journal of Haematology. 2022 Aug 1
• 5 citations
  CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.
  Dasom Lee, Akriti G Jain, Yehuda Deutsch, Jennifer Eatrides, Onyee Chan, Eric Padron, Andrew Kuykendall, Rami Komrokji, Jeffrey Lancet, David Sallman, Chetasi Talati, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
• 3 citations
  Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?
  Somedeb Ball, Akriti G Jain, Najla Al Ali, Yumeng Zhang, Onyee Chan, Andrew T Kuykendall, Kendra L Sweet, Jeffrey E Lancet, David M Swoboda, Eric Padron, Rami S Komrok...> ;American Journal of Hematology. 2022 May 1
• 5 citations
  Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts.
  David M Swoboda, Rashmi Kanagal-Shamanna, Andrew M Brunner, Thomas Cluzeau, Onyee Chan, Najla Al Ali, Guillermo Montalban-Bravo, Quinto J Gesiotto, Alexander Gavralidi...> ;Leukemia. 2022 Apr 1
• 5 citations
  MYC overexpression is associated with an early disease progression from MDS to AML.
  David Gajzer, Constantine Logothetis, David A. Sallman, Gregoire Calon, Abida Babu, Onyee Chan, Nicole D. Vincelette, Virginia O. Volpe, Najla Al Ali, Pukhraz Basra, C...> ;Leukemia Research. 2021 Dec 1
• 4 citations
  Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.
  Rami S. Komrokji, Megan Melody, Najla Al Ali, Onyee Chan, Virginia M. Klimek, Brian Ball, Mikkael A. Sekeres, George W. Lucas, Jaroslaw P. Maciejewski, David A. Sallma...> ;Leukemia & Lymphoma. 2021 Aug 27
• 13 citations
  Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.
  Anthony M. Hunter, Hannah Newman, Amy E. DeZern, David P. Steensma, Sandrine Niyongere, Gail J. Roboz, Qianxing Mo, Onyee Chan, Aaron T. Gerds, David A. Sallman, Willi...> ;Clinical Cancer Research. 2021 Jul 12
• 6 citations
  Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia
  Aline Renneville, Mrinal M. Patnaik, Onyee Chan, Eric Padron, Eric Solary> ;Leukemia. 2021 Jun 26
• 7 citations
  Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes
  Rami S. Komrokji, Virginia O. Volpe, Onyee Chan, Najla Al Ali, David M Swoboda, Andrew T. Kuykendall, Eric Padron, David A. Sallman> ;Blood. 2021 Sep 16
• 14 citations
  Chronic myelomonocytic leukemia diagnosis and management.
  Onyee Chan, Aline Renneville, Eric Padron> ;Leukemia. 2021 Mar 13
• Join now to see all

Abstracts/Posters

• Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts
  Onyee Chan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of ...
  Onyee Chan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...
  Onyee Chan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia
  Onyee Chan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients _70 Years with Acute M...
  Onyee Chan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
  Onyee Chan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
  Onyee Chan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019